Xencor Past Earnings Performance
Past criteria checks 0/6
Xencorhan disminuido a un ritmo medio anual de -16.8%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido growing a una tasa media anual de 14.3%.
Key information
-25.5%
Earnings growth rate
-24.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 10.8% |
Return on equity | -18.9% |
Net Margin | -74.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?
Mar 27There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise
Feb 27Xencor: Standing Out With XmAb Technology
Feb 03Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry
Jan 05Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially
Nov 13Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth
Nov 10Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Aug 08Xencor, Inc.'s (NASDAQ:XNCR) Shares May Have Run Too Fast Too Soon
Aug 12Xencor GAAP EPS of -$0.57 misses by $0.10, revenue of $30.18M misses by $3.83M
Aug 03Xencor: Capital-Efficient Platform Tech Play With A Lot Going On
Jun 03Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 35% Above Their Intrinsic Value Estimate
Feb 18Upgrade: Analysts Just Made A Huge Increase To Their Xencor, Inc. (NASDAQ:XNCR) Forecasts
Aug 06It's Unlikely That The CEO Of Xencor, Inc. (NASDAQ:XNCR) Will See A Huge Pay Rise This Year
Jun 20Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Apr 02Don't Ignore The Fact That This Insider Just Sold Some Shares In Xencor, Inc. (NASDAQ:XNCR)
Mar 06Time To Worry? Analysts Are Downgrading Their Xencor, Inc. (NASDAQ:XNCR) Outlook
Mar 02Are Investors Undervaluing Xencor, Inc. (NASDAQ:XNCR) By 39%?
Feb 26Revenue & Expenses BreakdownBeta
How Xencor makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 168 | -126 | 52 | 0 |
30 Sep 23 | 145 | -119 | 49 | 0 |
30 Jun 23 | 113 | -128 | 49 | 0 |
31 Mar 23 | 98 | -140 | 49 | 0 |
31 Dec 22 | 165 | -55 | 46 | 0 |
30 Sep 22 | 297 | 30 | 45 | 0 |
30 Jun 22 | 289 | 22 | 43 | 0 |
31 Mar 22 | 327 | 109 | 41 | 0 |
31 Dec 21 | 275 | 83 | 39 | 0 |
30 Sep 21 | 163 | -4 | 35 | 0 |
30 Jun 21 | 179 | 24 | 32 | 0 |
31 Mar 21 | 124 | -64 | 30 | 0 |
31 Dec 20 | 123 | -69 | 30 | 0 |
30 Sep 20 | 84 | -83 | 29 | 0 |
30 Jun 20 | 71 | -80 | 27 | 0 |
31 Mar 20 | 77 | -61 | 26 | 0 |
31 Dec 19 | 157 | 27 | 24 | 0 |
30 Sep 19 | 165 | 36 | 23 | 0 |
30 Jun 19 | 172 | 49 | 24 | 0 |
31 Mar 19 | 153 | 39 | 23 | 0 |
31 Dec 18 | 41 | -70 | 22 | 0 |
30 Sep 18 | 59 | -45 | 21 | 0 |
30 Jun 18 | 30 | -71 | 18 | 0 |
31 Mar 18 | 43 | -53 | 17 | 0 |
31 Dec 17 | 46 | -38 | 17 | 0 |
30 Sep 17 | 22 | -55 | 16 | 0 |
30 Jun 17 | 30 | -40 | 15 | 0 |
31 Mar 17 | 84 | 15 | 14 | 0 |
31 Dec 16 | 109 | 45 | 13 | 0 |
30 Sep 16 | 103 | 40 | 12 | 0 |
30 Jun 16 | 99 | 38 | 12 | 0 |
31 Mar 16 | 34 | -18 | 12 | 0 |
31 Dec 15 | 28 | -18 | 11 | 0 |
30 Sep 15 | 12 | -27 | 10 | 0 |
30 Jun 15 | 9 | -23 | 9 | 0 |
31 Mar 15 | 9 | -19 | 8 | 0 |
31 Dec 14 | 10 | -16 | 7 | 0 |
30 Sep 14 | 6 | -19 | 4 | 0 |
30 Jun 14 | 8 | -17 | 3 | 0 |
31 Mar 14 | 11 | 85 | 2 | 0 |
31 Dec 13 | 10 | 85 | 3 | 0 |
30 Sep 13 | 11 | 85 | 3 | 0 |
30 Jun 13 | 9 | 87 | 3 | 0 |
Beneficios de calidad: XNCR actualmente no es rentable.
Creciente margen de beneficios: XNCR actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: XNCR no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 16.8% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de XNCR en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: XNCR no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).
Return on Equity
Alto ROE: XNCR tiene un Rendimiento de los fondos propios negativo (-17.79%), ya que actualmente no es rentable.